EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
8.88
-0.15 (-1.66%)
At close: Jun 16, 2025, 3:59 PM
8.88
0.00%
After-hours: Jun 16, 2025, 06:52 PM EDT
-1.66% (1D)
| Bid | 7.78 |
| Market Cap | 611.05M |
| Revenue (ttm) | 56.04M |
| Net Income (ttm) | -146.78M |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -3.67 |
| Forward PE | -3.1 |
| Analyst | Buy |
| Ask | 9.5 |
| Volume | 327,784 |
| Avg. Volume (20D) | 829,206 |
| Open | 8.97 |
| Previous Close | 9.03 |
| Day's Range | 8.71 - 9.17 |
| 52-Week Range | 3.91 - 13.99 |
| Beta | 1.64 |
About EYPT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EYPT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EYPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+18.12%
EyePoint shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago
+2.36%
EyePoint Pharmaceuticals shares are trading higher after the company announced six-month results for its Phase 2 VERONA trial and stated the trial met its primary endpoint.
1 month ago · seekingalpha.com
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call TranscriptEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker ...
